Navigation Links
New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
Date:5/1/2012

CAESAREA, Israel, May 1, 2012 /PRNewswire/ --

CardioDex announces initial commercial use of a groundbreaking femoral access site closure device. Recent data from commercial use of the device on 41 patients at St Marien Hospital in Siegen Germany showed 100% success rate and no complications. "We are very excited about these new data that demonstrates that this device provides a viable treatment for a major unmet medical need due to the increasing use worldwide of percutaneous femoral access and the subsequent high rate of complications seen" said Dr. Hans Peter Hobbach, Deputy Chief of St Marien Hospital cardiac catheterization laboratory.

The new CardioDex thermal femoral artery closure device was used in 25 diagnostic cases and 16 interventional cases. The 100% success rate was obtained for normal or diseased femoral vessels with calcified plaque. According to Dr Shimon Eckhouse, Chairman and founder of CardioDex Ltd., "These very positive results confirm the data we observed in the first single-center clinical trial, that were presented earlier this year. This demonstrated performance of the Cardiodex closure device opens the door to a whole new and long awaited era for femoral arterial access and closure." One of the most exciting features of the device is the extremely short period before patient ambulation, diagnostic patients were ambulated within 2 hours and PCI (Percutaneous Coronary Intervention) patients were ambulated within 4 hours. There were no cases of hematoma or late bleeding, despite the fact that PCI patients were fully anticoagulated with heparin, aspirin and clopidogrel. Neither were there any cases of post procedural discomfort.

Method of action

The mechanism of action of the CardioDex device is based on controlled thermal closure of the arterial puncture site. The device consists of a temporary Nitinol anchor which is delivered via an existing introducer sheath and used to
'/>"/>

SOURCE CardioDex Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
2. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
3. Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
4. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
5. Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers
6. Accuri Cytometers Adds Automation to Its Revolutionary C6 Flow Cytometer(R) System With Commercial Launch of CSampler(TM)
7. ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384
8. Microfluidics Introduces Revolutionary Bottom-up Technology as a Platform for Continuous Pharmaceutical Manufacturing
9. Microfluidics and POWREX Launch Revolutionary Continuous Pharmaceutical Manufacturing Technology in Japan
10. A revolutionary breakthrough in terahertz remote sensing
11. A revolutionary breakthrough in terahertz remote sensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 ... announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... describes and evaluates animal biotechnology and ... pharmaceuticals as well as improvement in ...
(Date:5/28/2015)... May 27, 2015 Research and Markets( ... PharmaBiotech,s new report "Neuroprotection - Drugs, Markets ... This report describes the role of neuroprotection in ... the nervous system as well as in chronic ... the underlying mechanisms of damage to neural tissues ...
(Date:5/28/2015)... McKinney, Texas (PRWEB) May 28, 2015 ... products for use in applications such as animal ... fat and oil reduction in wastewater treatment plants ... be attending the World Pork Expo, June 3-5 ... earlier this year in a Wall Street Journal ...
(Date:5/28/2015)... , May 28, 2015 Biscayne Pharmaceuticals, ... potential of its growth hormone-releasing hormone (GHRH) technology will ... 2015 ASCO Annual Meeting. The data show that the ... anti-cancer GHRH blockers, is present on many primary breast ... suggest that GHRH antagonists could have broad anti-cancer potential ...
Breaking Biology Technology:Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed ... its U.K. clinical trial to evaluate the,anti-tumour ... with docetaxel (Taxotere(R)) in patients with advanced ... The,principal investigator is Professor Hardev Pandha of ...
... (Amex:,SVA), a vaccine-focused biotech company in China, announced today ... on Thursday, September 4,2008 at 9:00 a.m. Beijing Time. ... Xi Road, Haidian District, Beijing, PRC and at No. ... as of August 1,2008 will be eligible to vote ...
... today announced that the first patient has received an ... Company,s first oncology product, MM-121, a,fully human monoclonal antibody ... ErbB3 receptor., ErbB3 is a receptor in the ... cancer signaling. With the initiation of the Phase 1 ...
Cached Biology Technology:Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial 2Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial 3Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders 2Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist 2Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist 3
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... NEW YORK , May 19, 2015  Technology ... resources both internally and in the cloud. Passwords and ... the use of OTP and standards-based specifications such as ... that the outmoded use of passwords presents for BYOD, ... needs a unified biometric identity protocol. ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... emotional expression that is innate in human beings. This means ... phenomenon. However, the fear of being laughed at causes some ... as gelotophobia, a disorder that affects people in all cultures ... and another who suffers from gelotophobia? One of the aims ...
... DIEGO, Oct. 13 CareFusion Corporation (NYSE: CFN ), ... launch of the EnVe(TM) ventilator - a high-performance critical care ... the EnVe ventilator is 70-80 pounds lighter than other intensive ... technology to help hospitals increase the quality of patient care ...
... useful in electronics applications, Kansas State University engineers made ... Vikas Berry is a K-State assistant professor of chemical ... a single atom thick and discovered just five years ... its electronics properties -- Berry and Kabeer Jasuja, a ...
Cached Biology News:Fear of being laughed at crosses cultural boundaries 2Fear of being laughed at crosses cultural boundaries 3Fear of being laughed at crosses cultural boundaries 4CareFusion Launches EnVe(TM) Ventilator: 10-Pound High-Performance Critical Care Ventilator 2CareFusion Launches EnVe(TM) Ventilator: 10-Pound High-Performance Critical Care Ventilator 324-carat gold 'snowflakes' improve graphene's electrical properties 2
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
IHC detection kit for PCNA in cells and tissues...
Request Info...
... Immunogen: Synthetic peptide derived from ... WNT1 protein. Specificity: Reacts with ... Reactivity: Human Mouse (positive controls: ... cell lysates and mouse Mouse-1 cell ...
Biology Products: